These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 26206268)

  • 21. Pooled analysis of large and long-term safety data from the human papillomavirus-16/18-AS04-adjuvanted vaccine clinical trial programme.
    Angelo MG; David MP; Zima J; Baril L; Dubin G; Arellano F; Struyf F
    Pharmacoepidemiol Drug Saf; 2014 May; 23(5):466-79. PubMed ID: 24644063
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety of the AS04-adjuvanted human papillomavirus (HPV)-16/18 vaccine in adolescents aged 12-15 years: end-of-study results from a community-randomized study up to 6.5 years.
    Bi D; Apter D; Eriksson T; Hokkanen M; Zima J; Damaso S; Soila M; Dubin G; Lehtinen M; Struyf F
    Hum Vaccin Immunother; 2020 Jun; 16(6):1392-1403. PubMed ID: 31829767
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Risk of Spontaneous Abortion After Inadvertent Human Papillomavirus Vaccination in Pregnancy.
    Kharbanda EO; Vazquez-Benitez G; Lipkind HS; Sheth SS; Zhu J; Naleway AL; Klein NP; Hechter R; Daley MF; Donahue JG; Jackson ML; Kawai AT; Sukumaran L; Nordin JD
    Obstet Gynecol; 2018 Jul; 132(1):35-44. PubMed ID: 29889760
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Maternal and Infant Outcomes After Human Papillomavirus Vaccination in the Periconceptional Period or During Pregnancy.
    Lipkind HS; Vazquez-Benitez G; Nordin JD; Romitti PA; Naleway AL; Klein NP; Hechter RC; Jackson ML; Hambidge SJ; Lee GM; Sukumaran L; Kharbanda EO
    Obstet Gynecol; 2017 Sep; 130(3):599-608. PubMed ID: 28796684
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effectiveness of the AS04-adjuvanted HPV-16/18 vaccine in reducing oropharyngeal HPV infections in young females-Results from a community-randomized trial.
    Lehtinen M; Apter D; Eriksson T; Harjula K; Hokkanen M; Lehtinen T; Natunen K; Damaso S; Soila M; Bi D; Struyf F
    Int J Cancer; 2020 Jul; 147(1):170-174. PubMed ID: 31736068
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Peri-conceptional or pregnancy exposure of HPV vaccination and the risk of spontaneous abortion: a systematic review and meta-analysis.
    Tan J; Xiong YQ; He Q; Liu YM; Wang W; Chen M; Zou K; Liu XH; Sun X
    BMC Pregnancy Childbirth; 2019 Aug; 19(1):302. PubMed ID: 31426762
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Adverse pregnancy outcomes and infant mortality after quadrivalent HPV vaccination during pregnancy.
    Faber MT; Duun-Henriksen AK; Dehlendorff C; Tatla MK; Munk C; Kjaer SK
    Vaccine; 2019 Jan; 37(2):265-271. PubMed ID: 30503078
    [TBL] [Abstract][Full Text] [Related]  

  • 28. AS04-adjuvanted human papillomavirus-16/18 vaccination: recent advances in cervical cancer prevention.
    Schwarz TF
    Expert Rev Vaccines; 2008 Dec; 7(10):1465-73. PubMed ID: 19053203
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine for the prevention of cervical cancer and HPV-related diseases.
    Skinner SR; Apter D; De Carvalho N; Harper DM; Konno R; Paavonen J; Romanowski B; Roteli-Martins C; Burlet N; Mihalyi A; Struyf F
    Expert Rev Vaccines; 2016; 15(3):367-87. PubMed ID: 26902666
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy of the HPV-16/18 AS04-adjuvanted vaccine against low-risk HPV types (PATRICIA randomized trial): an unexpected observation.
    Szarewski A; Skinner SR; Garland SM; Romanowski B; Schwarz TF; Apter D; Chow SN; Paavonen J; Del Rosario-Raymundo MR; Teixeira JC; De Carvalho NS; Castro-Sanchez M; Castellsagué X; Poppe WA; De Sutter P; Huh W; Chatterjee A; Tjalma WA; Ackerman RT; Martens M; Papp KA; Bajo-Arenas J; Harper DM; Torné A; David MP; Struyf F; Lehtinen M; Dubin G
    J Infect Dis; 2013 Nov; 208(9):1391-6. PubMed ID: 24092907
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Quadrivalent HPV Vaccination and the Risk of Adverse Pregnancy Outcomes.
    Scheller NM; Pasternak B; Mølgaard-Nielsen D; Svanström H; Hviid A
    N Engl J Med; 2017 Mar; 376(13):1223-1233. PubMed ID: 28355499
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Risks and safety of pandemic H1N1 influenza vaccine in pregnancy: birth defects, spontaneous abortion, preterm delivery, and small for gestational age infants.
    Chambers CD; Johnson D; Xu R; Luo Y; Louik C; Mitchell AA; Schatz M; Jones KL;
    Vaccine; 2013 Oct; 31(44):5026-32. PubMed ID: 24016809
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Post-licensure safety surveillance for human papillomavirus-16/18-AS04-adjuvanted vaccine: more than 4 years of experience.
    Angelo MG; Zima J; Tavares Da Silva F; Baril L; Arellano F
    Pharmacoepidemiol Drug Saf; 2014 May; 23(5):456-65. PubMed ID: 24644078
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and 4vHPV vaccine administered according to two- or three-dose schedules in girls aged 9-14 years: Results to month 36 from a randomized trial.
    Leung TF; Liu AP; Lim FS; Thollot F; Oh HML; Lee BW; Rombo L; Tan NC; Rouzier R; De Simoni S; Suryakiran P; Hezareh M; Thomas F; Folschweiller N; Struyf F
    Vaccine; 2018 Jan; 36(1):98-106. PubMed ID: 29174109
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Is HPV vaccination in pregnancy safe?
    Bonde U; Joergensen JS; Lamont RF; Mogensen O
    Hum Vaccin Immunother; 2016 Aug; 12(8):1960-1964. PubMed ID: 27172372
    [TBL] [Abstract][Full Text] [Related]  

  • 36. HPV vaccines and pregnancy.
    Prescrire Int; 2015 Oct; 24(164):239-40. PubMed ID: 26594728
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Post hoc analysis of the PATRICIA randomized trial of the efficacy of human papillomavirus type 16 (HPV-16)/HPV-18 AS04-adjuvanted vaccine against incident and persistent infection with nonvaccine oncogenic HPV types using an alternative multiplex type-specific PCR assay for HPV DNA.
    Struyf F; Colau B; Wheeler CM; Naud P; Garland S; Quint W; Chow SN; Salmerón J; Lehtinen M; Del Rosario-Raymundo MR; Paavonen J; Teixeira JC; Germar MJ; Peters K; Skinner SR; Limson G; Castellsagué X; Poppe WA; Ramjattan B; Klein TD; Schwarz TF; Chatterjee A; Tjalma WA; Diaz-Mitoma F; Lewis DJ; Harper DM; Molijn A; van Doorn LJ; David MP; Dubin G;
    Clin Vaccine Immunol; 2015 Feb; 22(2):235-44. PubMed ID: 25540273
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sustained Immunogenicity of 2-dose Human Papillomavirus 16/18 AS04-adjuvanted Vaccine Schedules in Girls Aged 9-14 Years: A Randomized Trial.
    Huang LM; Puthanakit T; Cheng-Hsun C; Ren-Bin T; Schwarz T; Pellegrino A; Esposito S; Frenette L; McNeil S; Durando P; Rheault P; Giaquinto C; Horn M; Petry KU; Peters K; Azhar T; Hillemanns P; De Simoni S; Friel D; Pemmaraju S; Hezareh M; Thomas F; Descamps D; Folschweiller N; Struyf F
    J Infect Dis; 2017 Jun; 215(11):1711-1719. PubMed ID: 28591778
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Non-clinical safety assessment of single and repeated intramuscular administration of a human papillomavirus-16/18 vaccine in rabbits and rats.
    Segal L; Morelle D; Kaaber K; Destexhe E; Garçon N
    J Appl Toxicol; 2015 Dec; 35(12):1577-85. PubMed ID: 25752809
    [TBL] [Abstract][Full Text] [Related]  

  • 40. COVID-19 Booster Vaccination in Early Pregnancy and Surveillance for Spontaneous Abortion.
    Kharbanda EO; Haapala J; Lipkind HS; DeSilva MB; Zhu J; Vesco KK; Daley MF; Donahue JG; Getahun D; Hambidge SJ; Irving SA; Klein NP; Nelson JC; Weintraub ES; Williams JTB; Vazquez-Benitez G
    JAMA Netw Open; 2023 May; 6(5):e2314350. PubMed ID: 37204791
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.